MDRNA Plans Reverse Stock Split to Acquire Cequent, Changes Name
July 22, 2010
MDRNA Plans Reverse Stock Split to Acquire Cequent, Changes Name
MDRNA, now known as Marina Biotech, plans a 1-for-4 reverse stock split, which will enable it to have enough authorized shares to consummate the acquisition of Cequent.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MDRNA Aims to Market Cequent FAP Drug, File Three INDs by 2011
April 8, 2010 / Gene Silencing News - MDRNA to Acquire Cequent in $46M Stock Deal
April 1, 2010 / Gene Silencing News - Marina Biotech Advances FAP Drug into Phase I
March 17, 2011 / Gene Silencing News - Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi
January 6, 2011 / Gene Silencing News - Marina Gets Institutional Approval to Begin Phase I Study of FAP Drug
November 4, 2010 / Gene Silencing News